Literature DB >> 23983087

Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer.

James L Klosky1, Kathryn M Russell, Kristin E Canavera, Heather L Gammel, Jason R Hodges, Rebecca H Foster, Gilbert R Parra, Jessica L Simmons, Daniel M Green, Melissa M Hudson.   

Abstract

Effective vaccination is now available to prevent human papillomavirus (HPV), the most common sexually transmitted infection and cause of cervical cancer. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and identify factors associated with HPV vaccine initiation and completion. Mothers of daughters of ages 9 to 17 years with/without a history of childhood cancer (n = 235, Mage = 13.2 years, SD = 2.69; n = 70, Mage = 13.3 years, SD = 2.47, respectively) completed surveys querying HPV vaccination initiation and completion along with sociodemographic, medical, HPV knowledge and communication, and health belief factors, which may relate to vaccination outcomes. Multivariate logistic regression was used to identify factors that associate with HPV vaccination initiation and completion. Among cancer survivors, 32.6% initiated and 17.9% completed the three-dose vaccine series, whereas 34.3% and 20.0% of controls initiated and completed, respectively. Univariate analyses indicated no differences between cancer/no cancer groups on considered risk factors. Among all participants, multivariate logistic regression analyses found vaccine initiation associated with older age of daughter and physician recommendation, whereas increased perceived barriers associated with a decreased likelihood of initiation (all P < 0.05). Among those having initiated, risk factors for noncompletion included being non-White, increased perceived severity of HPV, and increased perceived barriers to vaccination (all P < 0.05). A minority of adolescents surviving childhood cancer has completed vaccination despite their increased risk for HPV-related complication. These results inform the prioritization of strategies to be included in vaccine promotion efforts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23983087      PMCID: PMC4264381          DOI: 10.1158/1940-6207.CAPR-13-0127

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  54 in total

1.  Recommended immunization schedules for persons aged 0 through 18 Years — United States, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-10       Impact factor: 17.586

2.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

3.  Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

Authors:  Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

4.  Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes.

Authors:  Loretta Brabin; Stephen A Roberts; Farah Farzaneh; Henry C Kitchener
Journal:  Vaccine       Date:  2006-02-09       Impact factor: 3.641

5.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt
Journal:  J Natl Cancer Inst       Date:  2010-02-05       Impact factor: 13.506

7.  Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV.

Authors:  Amanda F Dempsey; Gregory D Zimet; Robert L Davis; Laura Koutsky
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

10.  Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus.

Authors:  Luisa Barzon; Sergio Pizzighella; Luigi Corti; Carlo Mengoli; Giorgio Palù
Journal:  J Med Virol       Date:  2002-07       Impact factor: 2.327

View more
  10 in total

1.  Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer.

Authors:  James L Klosky; Brianne Favaro; Kelly R Peck; Jessica L Simmons; Kathryn M Russell; Daniel M Green; Melissa M Hudson
Journal:  J Cancer Surviv       Date:  2015-11-16       Impact factor: 4.442

Review 2.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

3.  Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer.

Authors:  Sharon M Castellino; Kristen E Allen; Katherine Pleasant; Graham Keyes; Katherine A Poehling; Janet A Tooze
Journal:  J Cancer Surviv       Date:  2019-07-24       Impact factor: 4.442

4.  Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.

Authors:  Melany Garcia; Cailey McGillicuddy; Elisa M Rodriguez; Kristopher Attwood; Jennifer Schweitzer; Scott Coley; Denise Rokitka; Nicolas F Schlecht
Journal:  Pediatr Blood Cancer       Date:  2022-09-12       Impact factor: 3.838

5.  Human Papillomavirus Vaccination of Adolescents with Chronic Medical Conditions: A National Survey of Pediatric Subspecialists.

Authors:  Annika M Hofstetter; Lauren Lappetito; Melissa S Stockwell; Susan L Rosenthal
Journal:  J Pediatr Adolesc Gynecol       Date:  2016-08-16       Impact factor: 1.814

6.  Caregiver Sexual and HPV Communication Among Female Survivors of Childhood Cancer.

Authors:  Courtney Peasant; Rebecca H Foster; Kathryn M Russell; Brianne E Favaro; James L Klosky
Journal:  J Pediatr Oncol Nurs       Date:  2015-12-14       Impact factor: 1.636

7.  Missed opportunities for concomitant HPV vaccination among childhood cancer survivors.

Authors:  Joemy M Ramsay; Heydon K Kaddas; Judy Y Ou; Deanna Kepka; Anne C Kirchhoff
Journal:  Cancer Med       Date:  2022-01-14       Impact factor: 4.452

8.  Human Papilloma Virus Vaccination in Patients with Rheumatic Diseases in France: A Study of Vaccination Coverage and Drivers of Vaccination.

Authors:  Emmanuelle David; Pascal Roy; Alexandre Belot; Pierre Quartier; Brigitte Bader Meunier; Florence A Aeschlimann; Jean-Christophe Lega; Isabelle Durieu; Christine Rousset-Jablonski
Journal:  J Clin Med       Date:  2022-07-16       Impact factor: 4.964

9.  HPV vaccination coverage for pediatric, adolescent and young adult patients receiving care in a childhood cancer survivor program.

Authors:  Lauren Thomaier; Danielle A Aase; Rachel I Vogel; Helen M Parsons; Karim T Sadak; Deanna Teoh
Journal:  Prev Med Rep       Date:  2022-09-07

Review 10.  Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review.

Authors:  Shannon E MacDonald; Airlie Palichuk; Linda Slater; Hailey Tripp; Laura Reifferscheid; Catherine Burton
Journal:  Hum Vaccin Immunother       Date:  2021-07-16       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.